Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 plus toripalimab vs investigator’s choice chemotherapy in PD-(L)1–refractory classical Hodgkin lymphoma
CTR20234002Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tifcemalimab, toripalimab in classical Hodgkin lymphoma (cHL), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jan 2024; status: active.
02
Drugs
tifcemalimabtoripalimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20234002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234002.